{"disease":{"id":"duchenne-muscular-dystrophy-early-stage","name":"duchenne muscular dystrophy early stage"},"drugs":{"marketed":[],"pipeline":[{"drug_id":"fordadistrogene-movaparvovec","indication_name":"Duchenne Muscular Dystrophy (early-stage)","indication_type":"pipeline","phase":"Phase 3","line_of_therapy":null,"is_primary_indication":false,"pivotal_trial_result":null,"pivotal_trial_p_value":null,"patient_population":null,"brand_name":"fordadistrogene movaparvovec","generic_name":"fordadistrogene-movaparvovec","company_name":"Pfizer Inc.","drug_phase":"discontinued","molecular_target":"Dystrophin gene (DMD); AAV9 receptor (AAVR)","drug_class":"Gene therapy; In vivo gene delivery","quality_score":null,"revenue":null,"mechanism":"Fordadistrogene movaparvovec delivers a functional dystrophin gene via AAV9 vector to restore muscle protein expression in Duchenne muscular dystrophy."}],"offLabel":[],"totalMarketed":0,"totalPipeline":1},"trials":{"data":[],"total":0},"guidelines":[],"source":"Drug Landscape verified database"}